27166-46-7

Usage

Uses

Used in Pharmaceutical Industry:
2,5-DIMETHYLPYRAZOLO[1,5-A]PYRIMIDIN-7-OL is used as a potential pharmaceutical candidate for the development of new drugs due to its potential medicinal properties and biological activity. It is being studied for its possible applications in the treatment of various diseases, with further research required to fully understand its potential uses and benefits in the field of medicine.

InChI:InChI=1/C8H9N3O/c1-5-4-8(12)11-7(9-5)3-6(2)10-11/h3-4,12H,1-2H3

Upstream product

• 31230-17-8 3-methyl-5-aminopyrazole 
• 141-97-9 ethyl acetoacetate 
• 31230-17-8 3-amino-5-methylpyrazole 

Downstream Products

• 136549-13-8 7-chloro-2,5-dimethyl-pyrazolo[1,5-a]pyrimidine 

Relevant academic research and scientific papers

HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY

A compound of formula (I) useful in the treatment of a Pneumoviridae viral infection.

2,6-DIMETHYL-N-((PYRIDIN-4-YL)METHYL)IMIDAZO[1,2-B]PYRIDAZIN-8-AMINE AND 2,5-DIMETHYL-N-[(PYRIDIN-4-YL)METHYL]PYRAZOLO[1,5-A]PYRIMIDIN-7-AMINE DERIVATIVES FOR TREATING VIRAL INFECTIONS

The compound is useful in therapy, in particular as an antiviral agent, e.g. in the treatment of an RNA viral infection. A pharmaceutical composition comprising the compound.

HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY

A compound of formula (I) or a pharmaceutically acceptable salt thereof, useful in therapy, in particular in the treatment of a viral infection or a disease linked to impaired or abnormal autophagy.

CONDENSED PYRIMIDINE OR PYRIDAZINE DERIVATIVES AS ANTIVIRAL AGENTS

A compound of formula (I) or a pharmaceutically acceptable salt thereof. The compound is a prodrug of a PI4KIIIβinhibitor and as such is useful as an antiviral agent. A pharmaceutical composition comprising the compound.

BIARYL KINASE INHIBITORS

The present disclosure is directed to biaryl compounds of formula (I) which can inhibit AAKl (adaptor associated kinase 1), compositions comprising such compounds and their use for treating e.g. pain, Alzheimer's disease, Parkinson's disease and schizophrenia.

Phenoxide leaving group SNAr strategy for the facile preparation of 7-amino-3-aryl pyrazolo[1,5-a]pyrimidines from a 3-bromo-7-phenoxypyrazolo[1,5-a]pyrimidine intermediate

We have discovered a 3-bromo-7-phenoxypyrazolo[1,5-a]pyrimidine intermediate that allows for the direct sequential funtionalization of the 3-position and 7-position of a pyrazolo[1,5-a]pyrimidine scaffold. The intermediate and general method described herein offer an improvement over prior methods, particularly in cases where multiple unique 3-aryl substituents are to be incorporated in conjunction with multiple unique 7-amino substituents.

PYRAZOLO [1,5-ALPHA] PYRIMIDINYL DERIVATIVES USEFUL AS CORTICOTROPIN-RELEASING FACTOR (CRF) RECEPTOR ANTAGONISTS

CRF receptor antagonists are disclosed which may have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in mammals. The CRF receptor antagonists of this invention have the following structure: (I); and pharmaceutically acceptable salts, esters, solvates, stereoisomers and prodrugs thereof, wherein R1, R2a, R2b, Y, Het, n, o, R6, Ar and R7 are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.

CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO

CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm-blooded animals, such as stroke. The CRF receptor antagonists of this invention have the following structure (I), including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, Y, Ar, and Het are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.

CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO

CRF receptor antagonists are disclosed which may have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in mammals, such as stroke. The CRF receptor antagonists of this invention have the following structure (a) including pharmaceutically acceptable salts, esters, solvates, stereoisomers, and prodrugs thereof, wherein R1, R2, R3, Y, Ar, and Het are as defined herein. Compositions containing a CRF receptor antagonist and a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.